Biomarkers in Oncology | Access and Reimbursement | EU5 | 2018
Biomarker-driven prescribing is entrenched in indications such as non-small-cell lung cancer (NSCLC) and malignant melanoma and is playing an increasingly important role in indications such as ovarian cancer. Although biomarker-associated therapies offer the advantage of selecting the patients most likely to respond to the treatment, these therapies are premium-priced and thus subject to payer restrictions and cost-containment strategies in the EU5. As several such therapies move toward launch in the EU5, we discuss how reimbursement restrictions influence oncologists’ drug selection and prescribing practices in NSCLC, malignant melanoma, and ovarian cancer and how nonclinical factors can help determine the commercial success of these therapies.
Questions Answered:
- What are the key driving forces and constraints that influence EU5 payers’ reimbursement decisions for biomarker-driven therapies for NSCLC, malignant melanoma, and ovarian cancer?
- How do market access and reimbursement policies at the national, regional, and local level shape prescribing preferences for biomarker-driven therapies?
- How do oncologists view select emerging biomarker-driven therapies, and do they expect to prescribe them? To what extent will EU5 payer policy likely impact uptake of these novel agents?
- What factors influence reimbursement of and access to companion biomarker tests?
Product Description:
Access & Reimbursement reports provide in-depth insight regarding the impact of payer policies on physician prescribing behavior so that clients can build theirmarket access strategy and optimize their brand positioning.
Content Highlights:
Actionable recommendations to optimize market access, market access success and stumbles, market access roadblocks, reimbursement dynamics, the impact of pricing and reimbursement, policy, and coverage on prescribing.
Scope of Report:
- Geography: France, Germany, Italy, Spain, and the United Kingdom (i.e., EU5).
- Primary research: Survey of 250 medical oncologists across the EU5 (50 per country) and interviews with 10 EU5 payers (2 per country).
- Key drugs covered: Iressa, Alecensa, Tagrisso, Tarceva, Giotrif, Xalkori, Zykadia, Keytruda, Yervoy, Opdivo, Tafinlar, Mekinist, Zelboraf, Cotellic, Lynparza.
